title: Cognition and behavior at school entry in children with congenital hypothyroidism treated early with high-dose levothyroxine.
abstract: OBJECTIVE
  To document cognition and behavior at school entry in these patients. Study design Eighteen children with congenital hypothyroidism (CH; 9 severe and 9 moderate, based on a surface of the knee epiphyses at diagnosis<or >or=0.05 cm(2)) treated from a median of 14 days with a median of 12.0 microg/kg per day of levothyroxine were evaluated at 5 years, 9 months, with the McCarthy Scale and the Questionnaire for Evaluation of Social Behavior, as were 40 control children.
  
  
  RESULTS
  The global IQs at 5 years, 9 months, were similar: medians (range) were 102 (87 to 133), 102 (84 to 135), and 115 (88 to 136) (not significant) for severe CH, moderate CH, and control children, respectively. The behavioral scores of CH children were within the normal range. However, the number of times when plasma TSH was >6.0 mIU/L during treatment was correlated positively with anxiety (P=.02) and inattention (P=.05), whereas the number of times TSH was <0.8 mIU/L was correlated with lower verbal scores (P=.05).
  
  
  CONCLUSIONS
  Children with severe CH treated early with a high dose of levothyroxine have normal global development and behavior at school entry.
authors.affiliation: Endocrinology Service, Sainte-Justine Hospital Research Center, Montreal, Quebec, Canada.
authors.forename: J
authors.initials: J
authors.lastname: Simoneau-Roy
authors.forename: S
authors.initials: S
authors.lastname: Marti
authors.forename: C
authors.initials: C
authors.lastname: Deal
authors.forename: C
authors.initials: C
authors.lastname: Huot
authors.forename: P
authors.initials: P
authors.lastname: Robaey
authors.forename: Guy
authors.initials: G
authors.lastname: Van Vliet
mesh_terms: D000704:Analysis of Variance; D002653:Child Behavior Disorders / Q000453:epidemiology / Q000517:prevention & control*; D002675:Child, Preschool; D003071:Cognition / Q000187:drug effects*; D003409:Congenital Hypothyroidism; D002658:Developmental Disabilities / Q000453:epidemiology / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000188:drug therapy*; D007231:Infant, Newborn; D008297:Male; D011446:Prospective Studies; D011792:Quebec / Q000453:epidemiology; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D013974:Thyroxine / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D013974:Thyroxine